Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca A Cancer J Clinicians. 2021;71:209–249.
   PubMed Web of Science ®Google Scholar
• Stomach cancer - statistics [Internet]. Cancer.net. 2019. Available from: https://www.cancer.net/cancer-types/stomach-cancer/statistics.
   Google Scholar
• Stomach Cancer Statistics | Gastric Cancer Statistics [Internet]. Available from: https://www.cancer.org/cancer/stomach-cancer/about/key-statistics.html.
   Google Scholar
• Karve S, Lorenzo M, Liepa AM, et al. Treatment patterns, costs, and survival among medicare-enrolled elderly patients diagnosed with advanced stage gastric cancer: analysis of a linked population-based cancer registry and administrative claims database. J Gastric Cancer. 2015;15:87.
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Robin Yabroff K, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. JNCI 2011 [cited 2019 Jul 6];103:117–128. DOI:10.1093/jnci/djq495
   PubMed Web of Science ®Google Scholar
• Hu H-M, Tsai H-J, Ku H-Y, et al. Survival outcomes of management in metastatic gastric adenocarcinoma patients. Sci Rep 2021 [cited 2022 Jan 26];11:23142. DOI:10.1038/s41598-021-02391-z
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Nccn.org. Gastric Cancer. Version 2.2022; 2022. Available from: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.
   Google Scholar
• Rihawi K, Ricci AD, Rizzo A, et al. Tumor-associated macrophages and inflammatory microenvironment in gastric cancer: novel translational implications. Int J Mol Sci. 2021;22:3805.
   PubMed Web of Science ®Google Scholar
• Ricci AD, Rizzo A, Rojas Llimpe FL, et al. Novel HER2-directed treatments in advanced gastric carcinoma: AnotHER paradigm shift? Cancers 2021 [cited 2022 Jun 20];13:1664. DOI:10.3390/cancers13071664
   PubMed Web of Science ®Google Scholar
• Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697.
   PubMed Web of Science ®Google Scholar
• Pan S, Li K, Huang B, et al. Efficacy and safety of immune checkpoint inhibitors in gastric cancer: a network meta-analysis of well-designed randomized controlled trials. Ann translat Med. 2021;9:290–290.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40.
   PubMed Web of Science ®Google Scholar
• Verma V, Sprave T, Haque W, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. Journal For ImmunoTherapy Of Cancer. 2018;6:6.
   PubMed Web of Science ®Google Scholar
• Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncology 2013 [cited 2019 Mar 29];18:381–390. DOI:10.1634/theoncologist.2012-0279
   Google Scholar
• Desai A, Gyawali B. Financial toxicity of cancer treatment: moving the discussion from acknowledgement of the problem to identifying solutions. EClinicalMedicine. 2020;100269. DOI:10.1016/j.eclinm.2020.100269
   PubMedGoogle Scholar
• Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 2016 [cited 2021 Mar 15];34:980–986. DOI:10.1200/JCO.2015.64.6620
   PubMed Web of Science ®Google Scholar
• Evans WK, de Oliveira C. Evaluating cost-effectiveness: an essential part of new cancer drug approvals. J Thorac Oncol. 2017 [cited 2022 Jan 26];12:1461–1463. DOI:10.1016/j.jtho.2017.08.013
   PubMed Web of Science ®Google Scholar
• Murray CJL, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 2000 [cited 2019 Jun 2];9:235–251. DOI:10.1002/(SICI)1099-1050(200004)9:3<235:AID-HEC502>3.0.CO;2-O
   PubMed Web of Science ®Google Scholar
• Haacker M, Hallett TB, Atun R. On discount rates for economic evaluations in global health. Health Policy Plann. 2019. DOI:10.1093/heapol/czz127
   Web of Science ®Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses. JAMA. 2016;316:1093.
   PubMed Web of Science ®Google Scholar
• U.S. Bureau of Labor Statistics. CPI Inflation Calculator Bls.gov. U.S. Bureau of Labor Statistics; 2019. Available from: https://www.bls.gov/data/inflation_calculator.htm.
   Google Scholar
• Soni M, Kiff C, Carroll R, et al. Nivolumab in gastric/gastroesophageal junction cancer: real-world data from UK early access to medicines scheme. Future Oncol. 2021;17:3163–3174.
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Fukuda T, Shimozuma K. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Br J Cancer. 2011;105:1273–1278.
   PubMed Web of Science ®Google Scholar
• Micromedex RED BOOK. Micromedex red book [Internet]. Available from: https://www.ibm.com/products/micromedex-red-book.
   Google Scholar
• Overview of the medicare physician fee schedule search | CMS [Internet]. cms.gov. Available from: https://www.cms.gov/medicare/physician-fee-schedule/search/overview.
   Google Scholar
• Briggs AH, Weinstein MC, Fenwick EAL, et al. Model Parameter Estimation and Uncertainty Analysis. Med Decis Mak. 2012;32:722–732.
   PubMed Web of Science ®Google Scholar
• Shu Y, Ding Y, Zhang Q. Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma in China. Front Oncol. 2022;12:12.
   Web of Science ®Google Scholar
• Jiang Y, Li Y, Wang LXW. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Int J Clin Pharm. 2022;44(2):499–506.
   PubMed Web of Science ®Google Scholar
• Zhang J, Huang Y, Xi G, et al. HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties. MAbs 2020 [cited 2021 Oct 15];12:1724751. DOI:10.1080/19420862.2020.1724751
   PubMed Web of Science ®Google Scholar
• EUROQOL. EQ-5D-5L – EQ-5D [Internet]. Euroqol.org. 2009. Available from: https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/.
   Google Scholar
• Modifications to the ICER value assessment framework for treatments for ultra-rare diseases Final Version [Internet]. 2017 [cited 2023 May 16]. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_URD_Framework_Adapt_013120.pdf.
   Google Scholar
• Verma V, Sprave T, Haque W, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):6. DOI:10.1186/s40425-018-0442-7
   PubMedGoogle Scholar
• Ventola CL. Cancer immunotherapy, part 3: challenges and future trends. P T. 2017;42:514–521. Available from. https://pubmed.ncbi.nlm.nih.gov/28781505/
   PubMedGoogle Scholar
• Geynisman DM, Chien C-R, Smieliauskas F, et al. Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review. Human Vaccines Immunother. 2014 [cited 2020 Oct 14];10(11):3415–3424. DOI:10.4161/hv.29407
   PubMed Web of Science ®Google Scholar
• Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing. JAMA. 2007;298:61.
   PubMed Web of Science ®Google Scholar
• Bernard DSM, Farr SL, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol. 2011;29:2821–2826.
   PubMed Web of Science ®Google Scholar
• Langa KM, Fendrick AM, Chernew ME, et al. Out-of-pocket health-care expenditures among older Americans with cancer. Value Health. 2004;7:186–194.
   PubMed Web of Science ®Google Scholar
• Smith GL, Lopez-Olivo MA, Advani PG, et al. Financial burdens of cancer treatment: a systematic review of risk factors and outcomes. J Natl Compr Canc Netw. 2019;17:1184–1192. Available from https://pubmed.ncbi.nlm.nih.gov/31590147/
   PubMed Web of Science ®Google Scholar
• Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer. JAMA. 2009;302:741. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657724/
   PubMed Web of Science ®Google Scholar
• Girard N, Corral J, Cortinovis D, et al. Second-line treatment selection in patients with non–small-cell lung cancer of adenocarcinoma histology: findings from a European survey of treating physicians. Clin Lung Cancer. 2017;18:e89–e97.
   PubMed Web of Science ®Google Scholar
• Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non–small-cell lung cancer. N Engl J Med. 2010;363:733–742. Available from https://www.ncbi.nlm.nih.gov/pubmed/20818875
   PubMed Web of Science ®Google Scholar
• Harada K, Zhao M, Shanbhag N, et al. Palliative care for advanced gastric cancer. Expert review of anticancer therapy. Expert Rev Anticancer Ther. 2020 [cited 2021 Jul 19];20(7):575–580. DOI:10.1080/14737140.2020.1781620
   PubMed Web of Science ®Google Scholar
• Kopecky K, Monton O, Rosman L, et al. Palliative interventions for patients with advanced gastric cancer: a systematic review. Chin Clin Oncol. 2022 [cited 2023 May 16];11(6):47–47. DOI:10.21037/cco-22-102
   PubMed Web of Science ®Google Scholar
• Abraham P, Wang L, Jiang Z, et al. Healthcare utilization and total costs of care among patients with advanced metastatic gastric and esophageal cancer. Future Oncol. 2021;17:291–299.
   PubMed Web of Science ®Google Scholar
• Tolley K, Goad C, Yi Y, et al. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ. 2012;14:749–759.
   PubMed Web of Science ®Google Scholar
• Matza LS, Phillips GA, Howell TA, et al. Estimating health state utilities associated with a rare disease: familial chylomicronemia syndrome (FCS). J Med Econ. 2020;23:978–984.
   PubMed Web of Science ®Google Scholar
• Swinburn P, Lloyd A, Nathan P, et al. Elicitation of health state utilities in metastatic renal cell carcinoma. Curr Med Res Opin. 2010;26:1091–1096.
   PubMed Web of Science ®Google Scholar
• Hudgens S, Briggs A, Tremblay G, et al. Comparison of methods to estimate health state utilities in Metastatic Breast Cancer (MBC). Value Health. 2014;17:A557.
   PubMed Web of Science ®Google Scholar
• Wong W, Yim YM, Kim A, et al. Assessment of Costs Associated with Adverse Events in Patients with Cancer. PLOS ONE. 2018;13(4):e0196007. DOI:10.1371/journal.pone.0196007
   PubMed Web of Science ®Google Scholar
• Hansen RN, Hackshaw MD, Nagar SP, et al. Health care costs among renal cancer patients using pazopanib and sunitinib. J Managed Care Specialty Pharm. 2015;21:37–44.
   PubMed Web of Science ®Google Scholar
• Cho SK, Hay JW, Barzi A. Cost-effectiveness analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer in the United States. Clin Colorectal Cancer. 2018;17:e751–e761.
   PubMed Web of Science ®Google Scholar
• Wu B, Dong B, Xu Y, et al. Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in a Health Resource–Limited Setting. PLoS ONE. 2012;7(8);e32530. DOI:10.1371/journal.pone.0032530
   PubMedGoogle Scholar